Board Member
Ultragenyx Pharmaceutical Inc. (RARE)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Emil D. Kakkis, M.D., Ph.D. is recorded as Board Member at Ultragenyx Pharmaceutical Inc. (RARE). Ultragenyx Pharmaceutical Inc. reported in an 8-K filed May 18, 2026 that Emil D. Kakkis, M.D., Ph.D. was appointed Class I Director, effective May 14, 2026. Ultragenyx Pharmaceutical Inc. reported in an 8-K filed June 13, 2023 that Emil D. Kakkis, M.D., Ph.D. was appointed Class I Director, effective June 7, 2023. Emil D. Kakkis, M.D., Ph.D. has spoken on 1 earnings call across 1 company, most recently for Ultragenyx Pharmaceutical Inc. on May 5, 2026.
“At the Annual Meeting, the Company's stockholders elected the Class I director nominees below to the Company's Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected.”
“At the Annual Meeting, the Company's stockholders elected the Class I director nominees below to the Company's Board of Directors to hold office until the 2026 Annual Meeting of Stockholders or until their successors are elected.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2023-06-07–present
Recorded roles and call appearances connecting this person to public companies.
Board Member
2023-06-07–present
Other people whose current roles at this company are on record from its filings.
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
